<DOC>
	<DOCNO>NCT01658553</DOCNO>
	<brief_summary>A multicenter , non-randomized , placebo-controlled , single dosing schedule , subject-blinded study evaluate effect GSK1120212 electrical activity heart compare placebo subject solid tumor cancer . All subject undergo Screening assessment within 21 day prior start study treatment determine eligibility enrollment study . Eligible subject receive study treatment administer period 15 day follow post-treatment follow-up visit . Study treatment ( GSK1120212-matched placebo ) blind subject . Subjects receive GSK1120212-matched placebo one day first 14 day dose . On day subject receive once-daily 2 mg dose GSK1120212 except Day 15 subject receive 3mg dose GSK1120212 12-lead ECG recording obtain continuous ECG recording obtain via 12-lead Holter monitor Study Days 1 15 subject clinical research unit . The effect GSK1120212 electrical activity heart determine time-matched ECGs obtain time point relative dosing day . Ambulatory blood pressure reading obtain continuous 24-hour recording via ambulatory blood pressure monitor The effect GSK1120212 blood pressure parameter determine blood pressure reading obtain time point relative dosing Study Days 1 15 . Serial blood sample analyze concentration study drug subject 's blood obtain time point relative dosing Study Days 1 15 . Subjects eligible continued treatment GSK1120212 may continue treatment rollover study MEK114375 ( drug study number ) . A post-treatment follow-up visit conduct within 28 day last dose study treatment subject continue treatment rollover study MEK114375 .</brief_summary>
	<brief_title>A Study Look Electrical Activity Heart Subjects With Solid Tumor Cancers , Before After Receiving Study Treatment , GSK1120212</brief_title>
	<detailed_description>GSK1120212 orally administer , potent highly selective small molecule inhibitor MEK1 ( mitogen-activated extracellular signal-regulated kinase-1 ) /MEK2 ( mitogen-activated extracellular signal-regulated kinase-2 ) activation kinase activity . As monotherapy , GSK1120212 show acceptable risk-benefit profile encourage efficacy various oncologic setting . This Phase I , single-sequence , placebo-controlled , singleblind , multicenter study design evaluate effect repeat oral dose GSK1120212 electrocardiographic parameter particular focus effect cardiac repolarization ( Corrected QT interval [ QTc ] duration ) compare placebo subject solid tumor cancer . A single dose placebo administer Study Day 1 follow administration once-daily 2 mg dose GSK1120212 13 day ( Study Days 2 14 ) Study Day 15 dose 3 mg GSK1120212 give . Digital 12-lead electrocardiogram ( ECGs ) extract continuous ECG recording obtain via Holter monitor Study Days 1 2 administration placebo Study Days 15 16 administration GSK1120212 . Pharmacokinetic sample time-matched Holter ECGs . This study also assess exposure-QTc relationship plasma concentration GSK1120212 effect , , cardiac repolarization , specifically QTc interval . Continuous 24-hour ambulatory blood pressure monitoring conduct assess effect GSK1120212 blood pressure parameter Study Days 1 15 . Safety assessment , include assessment adverse event , clinical laboratory test ( hematology clinical chemistry ) vital sign , perform throughout study . Following completion study treatment , eligible subject may transition open-label , rollover study MEK114375 continue treatment GSK1120212 .</detailed_description>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Inclusion Criteria Has provide sign , write informed consent . Male female , age great equal 18 year age time sign informed consent form . Has histologically cytologically confirm diagnosis solid tumor malignancy responsive standard therapy ( y ) approve therapy . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Able swallow retain oral medication . Has adequate baseline organ function follow : System : Hematologic absolute neutrophil count , Laboratory value : great equal 1.2 × 109/L ; System : Hematologic Hemoglobin , laboratory value : great equal 9 g/dL ; System : Hematologicplatelets , laboratory value : great equal 75 × 109/L ; System : Hematologic Prothrombin time ( PT ) , INR ( international normalizing ratio blood clot test ) ) Partial thromboplastin time ( PTT ) , laboratory value : less equal 1.5 time ULN ( Upper limit normal ) ; System Hepatic Total bilirubin , laboratory value : less equal 1.5 time ULN ; System : HepaticALT ( Alanine aminotransferase ) , laboratory value : less equal 2.5 time ULN ; System : RenalCreatine , laboratory value : less anad equal 1.5 time ULN ; System : RenalCalculated creatinine clearance , laboratory value : great equal 50 mL/min ; System : Renal24hour urine creatine clearance , laboratory value : great equal 50 mL/min ; System : CardiacLVEF , laboratory value : great equal LLN ( Lower limit normal ) ECHO MUGA ( Multigated acquisition scan ) . Abbreviations : ALT , alanine aminotransferase ; AST , aspartate aminotransferase ; ECHO , echocardiogram ; INR ; LLN , low limit normal ; LVEF , leave ventricular ejection fraction ; MUGA ; PT , prothrombin time ; PTT , partial thromboplastin time ; ULN , upper limit normal . INR great 1.5 time ULN acceptable case subject receive therapeutic anticoagulant warfarin long INR monitor study accord clinical practice ; Calculated CockcroftGault formula ; If LLN define give institution , ejection fraction must great equal 50 % . NOTE : Subjects aspartate aminotransferase ( AST ) , ALT bilirubin value outside range ( ) table due Gilbert 's syndrome asymptomatic gallstone exclude . Laboratory result obtain Screening use determine eligibility criterion . In situation laboratory result outside permitted range , investigator may opt retest subject subsequent withinrange screen result may use confirm eligibility . Have serum potassium , serum magnesium , total serum calcium level within normal limit . NOTE : If total serum calcium LLN , necessary determine albumincorrected total serum calcium level . Use follow calculation : Calcium ( mg/dL ) = measure total Calcium ( mg/dL ) + 0.8 ( 4.0 serum albumin [ g/dL ] ) NOTE : If serum potassium magnesium level LLN , supplementation permit order meet inclusion criterion . Subject retested follow supplementation . In order avoid situation subject dose study due electrolyte level fall LLN , strongly recommend maintain serum potassium level great 4 mEq ( Milliequivalent ) /L serum magnesium level great 2.2 mg/dL whenever possible . Slight elevation potassium magnesium upper limit normal may see supplementation exclude subject study entry . If female subject childbearing potential , must negative serum pregnancy test within 14 day first dose study treatment agree use effective contraception , define protocol . study 4 month follow last dose study treatment . History prior exposure MEK ( activate extracellular signalregulated kinase ) inhibitor disease progression receive treatment MEK inhibitor . Any following ECG finding : QTcF ( prefer ) QTcB ( interval correct heart rate Bazett 's formula ) interval great equal 480 msec ; PR ( Partial response ) interval great 220 msec less equal 110 msec ; Bradycardia define sinus rate le 50 beat per minute ( bpm ) Cardiac conduction abnormality denote follow : Evidence seconddegree ( type II ) thirddegree atrioventricular block ; Evidence ventricular preexcitation ; Electrocardiographic evidence complete leave bundle branch block ( LBBB ) NOTE : Right bundle branch block ( RBBB ) , incomplete LBBB incomplete RBBB exclusionary ONLY QRS ( name combination graphical deflection see typical electrocardiogram ) duration great 120 msec ; Intraventricular conduction delay QRS duration great 120 msec ; Evidence atrial fibrillation history atrial fibrillation within past 6 month ; Presence cardiac pacemaker History evidence one follow cardiovascular condition within past 6 month : Class II , III , IV heart failure define New York Heart Association ; Cardiac angioplasty stenting ; Myocardial infarction ; Unstable angina ; Symptomatic peripheral vascular disease clinically significant cardiac disease ; Cardiac metastases Left ventricular ejection fraction ( LVEF ) , measure ECHO MUGA scan , institutional LLN , LLN exist institution , le 50 % Personal family history longQT syndrome . Treatmentrefractory hypertension define blood pressure SBP ( Systolic blood pressure ) great 140 mmHg and/or DBP ( Diastolic blood pressure ) great 90 mmHg control antihypertensive therapy lifestyle modification . Anticancer therapy ( e.g. , chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , major surgery ) within 21 day prior enrollment ; chemotherapy regimens without delayed toxicity within 14 day prior enrollment ; use investigational anticancer drug within 28 day precede first dose study treatment . NOTE : Subjects history prior anthracycline exposure exclude . Current use prohibit medication ( ) require medication treatment study treatment . NOTE : This include medication list drug generally accept QTdrug.org ( Advisory Board Arizona Center Education Research Therapeutics risk cause Torsade de pointes ( available : http : //www.azcert.org/medicalpros/druglists/bycategory.cfm ) . Current use therapeutic warfarin . NOTE : Low molecular weight heparin prophylactic lowdose warfarin permit . Any unresolved toxicity great equal Grade 2 , except alopecia Grade 2 anemia , ( NCICTCAE ) , version 4.0 , previous anticancer therapy . Preexisting Grade 2 great peripheral neuropathy . History current evidence/risk RVO CSR : History RVO ( Retinal vein occlusion ) CSR ( Central serous retinopathy ) , predispose factor RVO CSR ( i.e. , uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease hypertension diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) ; Visible retinal pathology assess ophthalmic examination consider risk factor RVO CSR : Evidence new optic disc cupping ; Intraocular pressure &gt; 21 mmHg measure tonography History interstitial lung disease pneumonitis . Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . NOTE : Subjects previously treat condition stable central nervous system disease ( verified consecutive imaging study ) great 3 month , asymptomatic currently take corticosteroid , stable dose corticosteroid least 30 day prior Study Day 1 permit . Presence clinically significant gastrointestinal ( GI ) abnormality may affect absorption study treatment ( ) include , limited : Active , uncontrolled GI disease ; Malabsorption syndrome ; Substantial resection stomach , small bowel colon . If clarification need whether condition significantly affect absorption study treatment ( ) , contact GSK Medical Monitor . History presence hepatic insufficiency ( exclude metastatic hepatic carcinoma ) . Uncontrolled medical condition ( i.e. , diabetes mellitus , hypertension ) , psychological , familial , sociological , geographical condition permit compliance protocol ; unwillingness inability follow procedure require protocol . Lactating actively breastfeed female . Known immediate delay hypersensitivity reaction idiosyncrasy DMSO ( Dimethyl Sulfoxide ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>solid tumor</keyword>
</DOC>